专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07105544B2 Substituted alkyl amido piperidines 失效
公开(公告)号：US07105544B2
公开(公告)日：2006-09-12
申请号：US10345063
申请日：2003-01-14
申请人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
发明人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
IPC分类号： A61K31/445 , C07D211/26
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

2. 发明授权

US07199135B2 Substituted alkyl amido piperidines 失效
标题翻译：取代的烷基酰氨基哌啶
公开(公告)号：US07199135B2
公开(公告)日：2007-04-03
申请号：US10753057
申请日：2004-01-06
申请人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
发明人： Mohammad R. Marzabadi , John M. Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
IPC分类号： A61K31/445 , C07D401/04
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

3. 发明授权

US07329656B2 Arylthiobenzylpiperidine derivatives 失效
标题翻译：芳硫基苄基哌啶衍生物
公开(公告)号：US07329656B2
公开(公告)日：2008-02-12
申请号：US11231601
申请日：2005-09-21
申请人： Mohammad R. Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
发明人： Mohammad R. Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
IPC分类号： A61K31/4545 , A61K31/444 , A61K31/5377 , C07D211/04 , C07D401/04 , C07D413/14
CPC分类号： C07D401/04 , C07D211/26 , C07D211/62 , C07D401/12 , C07D401/14
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

4. 发明授权

US07473698B2 Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof 失效
标题翻译：仲氨基苯胺哌啶类作为MCH1拮抗剂及其应用
公开(公告)号：US07473698B2
公开(公告)日：2009-01-06
申请号：US10518675
申请日：2003-07-03
申请人： Mohammad R. Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John E. De Leon , John Wetzel
发明人： Mohammad R. Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John E. De Leon , John Wetzel
IPC分类号： A61K31/4465
CPC分类号： C07D211/26 , C07D401/12
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

5. 发明申请

US20080139555A1 Arylthiobenzylpiperidine Derivatives 审中-公开
标题翻译：芳硫基苄基哌啶衍生物
公开(公告)号：US20080139555A1
公开(公告)日：2008-06-12
申请号：US12028094
申请日：2008-02-08
申请人： Mohammad R. Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
发明人： Mohammad R. Marzabadi , Yu Jiang , Chien-An Chen , Kai Lu , Kim Andersen
IPC分类号： A61K31/4545 , A61K31/5377 , C07D413/14 , C07D401/14 , A61P25/24 , A61P25/00 , A61P3/04 , C07D403/14 , A61K31/496
CPC分类号： C07D401/04 , C07D211/26 , C07D211/62 , C07D401/12 , C07D401/14
摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

6. 发明授权

US07446204B2 Amino substituted aryloxybenzylpiperidine derivatives 失效
标题翻译：氨基取代的芳氧基苄基哌啶衍生物
公开(公告)号：US07446204B2
公开(公告)日：2008-11-04
申请号：US11230849
申请日：2005-09-20
申请人： Mohammad R. Marzabadi , Chien-An Chen , Yu Jiang , Kai Lu , Kim Andersen
发明人： Mohammad R. Marzabadi , Chien-An Chen , Yu Jiang , Kai Lu , Kim Andersen
IPC分类号： C07D211/14 , A61K31/451
CPC分类号： C07D211/26 , C07D211/34 , C07D401/12 , C07D403/12
摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

7. 发明授权

US07335665B2 Spirocyclic piperidines as MCH1 antagonists and uses thereof 失效
标题翻译：螺环哌啶类作为MCH1拮抗剂及其应用
公开(公告)号：US07335665B2
公开(公告)日：2008-02-26
申请号：US10518939
申请日：2003-07-03
申请人： Mohammad R. Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John E. De Leon , John Wetzel , Kim Andersen
发明人： Mohammad R. Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John E. De Leon , John Wetzel , Kim Andersen
IPC分类号： A61K31/438 , C07D221/20 , C07D491/10
CPC分类号： C07D221/20 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D491/10
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

8. 发明授权

US06727264B1 Substituted anilinic piperidines as MCH selective antagonists 失效
标题翻译：取代的苯胺哌啶类作为MCH选择性拮抗剂
公开(公告)号：US06727264B1
公开(公告)日：2004-04-27
申请号：US10188434
申请日：2002-07-03
申请人： Mohammad R. Marzabadi , John Wetzel , John E. DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
发明人： Mohammad R. Marzabadi , John Wetzel , John E. DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
IPC分类号： A61K31445
CPC分类号： C07D401/04 , C07D211/26 , C07D211/28 , C07D211/90 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

9. 发明授权

US07067534B1 Substituted anilinic piperidines as MCH selective antagonists 失效
标题翻译：取代的苯胺哌啶类作为MCH选择性拮抗剂
公开(公告)号：US07067534B1
公开(公告)日：2006-06-27
申请号：US10719358
申请日：2003-11-21
申请人： Mohammad R. Marzabadi , John Wetzel , John E. DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
发明人： Mohammad R. Marzabadi , John Wetzel , John E. DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
IPC分类号： A61K31/445 , C07D401/06
CPC分类号： C07D401/04 , C07D211/26 , C07D211/28 , C07D211/90 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

10. 发明申请

US20060173027A1 Spirocvclic piperidines as mch1 antagonists and uses thereof 失效
标题翻译：作为mch1拮抗剂的西吡唑哌啶及其用途
公开(公告)号：US20060173027A1
公开(公告)日：2006-08-03
申请号：US10518939
申请日：2003-07-03
申请人： Mohammad Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John De Leon , John Wetzel , Kim Andersen
发明人： Mohammad Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John De Leon , John Wetzel , Kim Andersen
IPC分类号： A61K31/4747
CPC分类号： C07D221/20 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D491/10
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式